{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:00:54Z","timestamp":1789214454231,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.yexcr.2022.113192","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T12:05:41Z","timestamp":1652270741000},"page":"113192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting PI3K\/AKT\/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax"],"prefix":"10.1016","volume":"417","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-044X","authenticated-orcid":false,"given":"Hongcai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubair","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2022.113192_bib1","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.yexcr.2022.113192_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12943-016-0571-x","article-title":"Targeting acute myeloid leukemia stem cell signaling by natural products","volume":"16","author":"Siveen","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.yexcr.2022.113192_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.yexcr.2022.113192_bib4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexcr.2022.113192_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2022.113192_bib6","first-page":"e724","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial, the Lancet","volume":"7","author":"DiNardo","year":"2020","journal-title":"Haematology"},{"key":"10.1016\/j.yexcr.2022.113192_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.yexcr.2022.113192_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yexcr.2022.113192_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc2297","article-title":"Diagnosing and exploiting cancer's addiction to blocks in apoptosis","volume":"8","author":"Letai","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.yexcr.2022.113192_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1097-2765(01)00320-3","article-title":"BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis","volume":"8","author":"Cheng","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.yexcr.2022.113192_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","article-title":"Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics","volume":"2","author":"Letai","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.yexcr.2022.113192_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.yexcr.2022.113192_bib13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/379554a0","article-title":"Bax-independent inhibition of apoptosis by Bcl-XL","volume":"379","author":"Cheng","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2022.113192_bib14","first-page":"1149","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity, the Lancet","volume":"11","author":"Wilson","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.yexcr.2022.113192_bib15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-Mimetic drugs: blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.yexcr.2022.113192_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2022.113192_bib17","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexcr.2022.113192_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexcr.2022.113192_bib19","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexcr.2022.113192_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1158\/2159-8290.CD-19-0577","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"9","author":"Correction","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexcr.2022.113192_bib21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexcr.2022.113192_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccell.2019.09.008","article-title":"Venetoclax in lymphoid malignancies: new insights, more to learn","volume":"36","author":"Thijssen","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.yexcr.2022.113192_bib23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Gen. Dev."},{"key":"10.1016\/j.yexcr.2022.113192_bib24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","author":"Teh","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2022.113192_bib25","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2022.113192_bib26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Gen. Dev."},{"key":"10.1016\/j.yexcr.2022.113192_bib27","series-title":"Inhibition of the Anti-apoptotic Protein MCL-1 Severely Suppresses Human Hematopoiesis","author":"Bohler","year":"2020"},{"key":"10.1016\/j.yexcr.2022.113192_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082907","article-title":"The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells","volume":"21","author":"Nepstad","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2022.113192_bib29","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1002\/jcp.26786","article-title":"Mcl-1 targeting could be an intriguing perspective to cure cancer","volume":"233","author":"De Blasio","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.yexcr.2022.113192_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yexcr.2022.113192_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2017.11.006","article-title":"Dueling for dual inhibition: means to enhance effectiveness of PI3K\/Akt\/mTOR inhibitors in AML","volume":"32","author":"Herschbein","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.yexcr.2022.113192_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-020-0112-3","article-title":"Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia","volume":"5","author":"Luedtke","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.yexcr.2022.113192_bib33","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41375-019-0652-0","article-title":"A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies","volume":"34","author":"Phillips","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2022.113192_bib34","doi-asserted-by":"crossref","first-page":"15752","DOI":"10.1038\/s41598-018-33982-y","article-title":"Repression of Mcl-1 expression by the CDC7\/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML","volume":"8","author":"O' Reilly","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2022.113192_bib35","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2014-10-605584","article-title":"Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies","volume":"125","author":"Peterson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2022.113192_bib36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41467-017-02693-9","article-title":"Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexcr.2022.113192_bib37","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/0008-5472.CAN-12-1365","article-title":"Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism","volume":"73","author":"Rahmani","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2022.113192_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2014.03.001","article-title":"PI3K\/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced","volume":"348","author":"Jebahi","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.yexcr.2022.113192_bib39","first-page":"1","article-title":"The phosphatidylinositol 3-kinase\/Akt\/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients","author":"Martelli","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2022.113192_bib40","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/leu.2014.305","article-title":"Dual PI3K\/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia","volume":"29","author":"Sandh\u00f6fer","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2022.113192_bib41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/aps.2016.121","article-title":"The PI3K\/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia","volume":"38","author":"Deng","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.yexcr.2022.113192_bib42","first-page":"2879","article-title":"Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia","volume":"96","author":"Zwaan","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2022.113192_bib43","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/1078-0432.CCR-10-1102","article-title":"Dual inhibition of PI3K and mTORC1\/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia","volume":"16","author":"Chapuis","year":"2010","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.yexcr.2022.113192_bib44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","article-title":"Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells","volume":"21","author":"Muranen","year":"2012","journal-title":"Cancer Cell"}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482722001859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482722001859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:41:31Z","timestamp":1757997691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482722001859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0014482722001859"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2022.113192","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PI3K\/AKT\/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2022.113192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113192"}}